BCRX
BioCryst Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$9.96
−1.29%Aug 25, 2026, 11:01 UTC
BioCryst announced that Japan approved ORLADEYO for pediatric hereditary angioedema patients aged 2 and older, expanding availability of the oral prophylactic therapy.
Source:Aug 5, 2026, 11:00 UTC
BioCryst Pharmaceuticals began shipping ORLADEYO oral pellets to pediatric patients on August 3, 2026.
Aug 5, 2026, 11:00 UTC
BioCryst Pharmaceuticals completed enrollment in ALPHA-ORBIT, the ongoing pivotal study of navenibart.
Aug 5, 2026, 11:00 UTC
BioCryst Pharmaceuticals reported second quarter 2026 financial results with total net revenue of $218.3 million and ORLADEYO net revenue of $158.2 million, and maintained full year 2026 ORLADEYO revenue guidance of $625 to $645 million while increasing total revenue guidance to $690 million to $715 million.
Jun 29, 2026, 11:00 UTC
BioCryst Pharmaceuticals winds down internal discovery programs and closes its Birmingham research facility as part of a strategic shift toward external innovation.
Source: